Respiratory Disease Vaccine Market Size, Share & Trends Analysis Report By Type (Viral, Bacterial, Combination), By Age Group, By Infection (COVID-19, Influenza), By Distribution Channel, By Region, And Segment Forecasts, 2023 - 2030

Report Overview

The global respiratory disease vaccine market size was estimated at USD 92.23 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 1.21% from 2023 to 2030. The market is witnessing growth due to factors such as the rising prevalence of respiratory diseases, which, accounts for around 545 million cases, representing an estimated 7.4% of the total population, growing focus on the importance of vaccination, occurrence of the pandemic, and emergency preparedness. The rising global burden of diseases, including influenza, pneumonia, pertussis, and respiratory syncytial virus (RSV), is a significant driver for the growth of the respiratory disease vaccine market. The need to prevent and control these diseases fuels the demand for effective vaccines.

There is increasing recognition of the importance of prevention in reducing the burden of respiratory diseases. Public health campaigns, educational initiatives, and healthcare provider recommendations have raised awareness among individuals and communities about the benefits of respiratory disease vaccines.

Every year, RSV is responsible for the deaths of approximately 33,000 individuals aged above 60 years in healthcare settings located in high-income countries. Additionally, it causes an estimated 46,000 deaths among infants under the age of 7 months, with majority of these fatalities occurring in developing nations. Over the years, there have been efforts made by competitive players operating in the market for development of RSV vaccine. With continued efforts, GSK plc, received FDA approval for its RSV vaccine in May 2023, further Pfizer has also announced plans to market its RSV vaccine in the third quarter of 2023.

Moreover, technological advancements in research and development have led to the introduction of more effective and targeted respiratory disease vaccine. Improved formulations, adjuvants, and delivery systems enhance vaccine efficacy, immunogenicity, and safety, contributing to market growth. Furthermore, continued investment in research and development by manufacturers and pharmaceutical companies further fuels the growth of the respiratory disease vaccine market.

However, the development, testing, and approval processes are complex and time-consuming. Regulatory requirements and stringent safety standards are one of the major restraints for vaccine manufacturers, leading to delays in vaccine availability and market entry. Moreover, ensuring an adequate and consistent supply of vaccines and their equitable distribution can be a logistical challenge. Maintaining cold chain storage and transportation, especially in resource-limited settings, is expected to highly impact the availability and accessibility of respiratory disease vaccines.

Type Insights

The viral vaccine segment held the largest market share of 54.83% in 2022 in the market owing to an increasing viral respiratory diseases, such as influenza, respiratory syncytial virus (RSV), and coronavirus infections. For instance, according to CDC, in May 2023, there are an estimated 27 million cases of influenza, causing deaths of 19,000 people in the U.S. Furthermore, collaboration between vaccine manufacturers, research institutions, and regulatory agencies has facilitated the development and approval. For instance, in April 2020, Sanofi entered into a collaboration with GSK plc for the development of adjuvanted COVID-19 vaccine. Such product launches is further anticipated to propel the growth of the segment.

The bacterial vaccine segment is expected to show fastest growth rate over the forecast period. The growth of the segment is attributed to the rising prevalence of bacterial respiratory infections, including pneumococcal pneumonia, Haemophilus influenzae type b (Hib) infections, and pertussis (whooping cough). For instance, according to WHO, Pneumonia is estimated to account for 14% of total deaths in children, moreover, according to CDC, there are an estimated 2,000-6,000 cases of pertussis each year in U.S. The need to prevent and control these infections is driving the demand for bacterial respiratory vaccines.

Age Group Insights

The adult segment held the largest market share of 76.54% in 2022 in respiratory disease vaccine market. The growth of the segment is attributed to the rising prevalence of respiratory diseases among the adult population. The global population is aging, with a higher proportion of older adults who are at increased risk of respiratory infections and their complications. This has led to a greater emphasis on immunization efforts targeting this age group, including the development and promotion of vaccines specifically designed for adults. Moreover, the rising awareness among adult population regarding the importance of vaccination is further anticipated to drive segment growth.

The pediatric segment is expected to show fastest growth rate over the forecast period. The growth of the segment is attributed to the high vaccinations provided to infants and newborns for tackling various respiratory diseases. For instance, the MMR vaccine is given to protect against measles, mumps, and rubella which is typically administered first at around 12-15 months of age, and the second between 4-6 years of age. Furthermore, the growth of respiratory vaccines for pediatrics is fueled by factors such as increasing awareness, expanded immunization schedules, technological advancements, government initiatives, the burden of respiratory diseases, and the impact of the COVID-19 pandemic. Continued focus on prevention and vaccination efforts for pediatric respiratory infections is expected to drive further growth in this market.

Infection Insights

COVID-19 segment held the largest market share of 68.02% in 2022 in respiratory disease vaccine market. With the rising concerns to prevent the spread of SARS-CoV-2 infection the global scientific community has rapidly developed and authorized several COVID-19 vaccines. These were approved with an aim to stop the occurrence and spread of virus. A number of vaccine were developed including the mRNA-based developed by Pfizer-BioNTech and Moderna, viral vector developed by AstraZeneca and Johnson & Johnson, and inactivated developed by SINOVAC and Bharat Biotech. These vaccines were used for immunization of majority of the population during the pandemic which has propelled the overall growth of the segment.

The Respiratory Syncytial Virus (RSV) segment is expected to show the fastest growth rate over the forecast period. The growth of the segment is attributed to the rising prevalence of RSV associated infections and growing initiatives by key players operating in the market for the development of RSV vaccine. The virus is estimated to affect around 33 million people globally each year which propels the need for the development of a vaccine that would help in preventing the occurrence of infection. The segment is anticipated to show significant growth owing to the increasing number of product launches over the forecast period. For instance, GSK’s RSV vaccine was launched in May 2023, and Moderna’s investigational vaccine met end-point efficacy in Phase 3 trial in January 2023, which is expected to be launched in the market in the third quarter of 2023.

Distribution Channel Insights

The hospital and retail pharmacies segment held the largest share of 54.16% in the respiratory disease vaccine market in 2022, which can be attributed to the rising prevalence of respiratory diseases among the population. Hospitals have dedicated healthcare professionals, such as nurses and doctors, who are trained to administer vaccines, including respiratory vaccines. They provide vaccination services to patients within hospital settings, particularly those at higher risk of respiratory diseases, such as the elderly or individuals with underlying health conditions. Moreover, retail pharmacies often provide walk-in vaccination services, allowing individuals to receive respiratory vaccines without an appointment. This flexibility enables managing busy schedules and encouraging vaccine uptake among the general population.

The government supplies segment is projected to grow at the fastest rate over the forecast period. The growth of the segment is attributed to the rising role of government in promoting and facilitating vaccination programs globally. For instance, the National Vaccine Program was established with an aim to focus on research, development, safety and efficacy testing, and distribution. Moreover, governments have been constantly focusing on collaboration with international organizations, such as the WHO and the Pan American Health Organization (PAHO), to make vaccines accessible and affordable further ensuring their equitable distribution. Furthermore, during the pandemic, governments played a major role by mobilizing vaccination campaigns to control the spread of infections.

Regional Insights

Asia Pacific held largest market share of 32.29% in 2022 and is expected to maintain a dominant position, in terms of share, throughout the forecast period. The growth of the market in the region is due to the increasing burden of respiratory diseases, growing government initiatives, and a growing aging population. The region has a rapidly aging population, which is susceptible to respiratory infections, especially pneumonia and influenza. Vaccination has been playing a vital role in protecting the elderly from severe complications and reducing the burden on healthcare systems. Moreover, key players have been focusing on expanding their presence in the region owing to the high opportunity in the region attributable to the high disease prevalence. For instance, in February 2022, Moderna, Inc. announced plans to expand its presence in the region with new subsidiaries in Taiwan, Malaysia, Singapore, Hong Kong, and Taiwan to scale up manufacturing and distribution of mRNA and COVID-9 vaccine.

North America is estimated to show the fastest growth over the forecast period. The growth of the market in the region is attributed to the rising awareness among the population regarding vaccination and the growing geriatric population. The region shows high adoption of respiratory vaccination majorly in U.S. owing to the rising need of preventing respiratory diseases. Vaccines for respiratory diseases, including influenza and pneumococcal infections, are widely accessible in the region through healthcare providers, pharmacies, and public health clinics. Moreover, advancements in vaccine technologies, such as mRNA-based vaccines, have been pioneered by key players in the region, leading to the rapid development and deployment of COVID-19 vaccines. For instance, in February 2021, Johnson & Johnson Services, Inc. received EUA from FDA for its single-dose COVID-19 vaccine.

Key Companies & Market Share Insights

The key players operating in the field of vaccine development are continually concentrating on introducing and improving existing technologies that help to improve patient outcomes and considerably increase healthcare effectiveness and efficiency. For Instance, in May 2023, GSK plc received FDA approval for Arexvy, first RSV vaccine approved globally for older adults. Some prominent players in the global respiratory disease vaccine market include:

• GSK plc.

• Johnson & Johnson Services, Inc.

• Pfizer Inc.

• Sanofi

• Serum Institute of India Pvt. Ltd.

• SINOVAC

• Bavarian Nordic

• Merck & Co., Inc.

• AstraZeneca

• EMERGENT

• Novavax

• INOVIO Pharmaceuticals

• Moderna Inc.

Respiratory Disease Vaccine Market Report Scope

Global Respiratory Disease Vaccine Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this report, Grand View Research has segmented the global respiratory disease vaccine market report based on type, age group, infection, distribution channel, and region:

• Type Outlook (Revenue, USD Billion, 2018 - 2030)

  • Viral Vaccine

  • Bacterial Vaccine

  • Combination Vaccine

• Age Group Outlook (Revenue, USD Billion, 2018 - 2030)

  • Pediatric

  • Adult

• Infection Outlook (Revenue, USD Billion, 2018 - 2030)

  • COVID-19

  • Influenza

  • Respiratory Syncytial Virus (RSV)

  • Pneumonia

  • Others

• Distribution Channel Outlook (Revenue, USD Billion, 2018 - 2030)

  • Hospital & Retail Pharmacies

  • Government Suppliers

  • Others

• Regional Outlook (Revenue, USD Billion, 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • U.K.

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East and Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait